News
LDXHF
0.076
NaN%
--
Lumos Signs Portugal Distribution Agreement for FebriDx®
TipRanks · 4d ago
Lumos Diagnostics Reports 2026 AGM Voting Results
TipRanks · 11/13 03:30
Lumos Reports FebriDx CLIA Waiver and U.S. Site Expansion
TipRanks · 11/12 22:10
Lumos Expands FebriDx® Across 97 Additional WellStreet Urgent Care Locations
Barchart · 11/11 07:20
Bell Potter Keeps Their Buy Rating on Lumos Diagnostics Holdings Ltd. (LDX)
TipRanks · 11/10 10:36
Bell Potter Remains a Buy on Lumos Diagnostics Holdings Ltd. (LDX)
TipRanks · 10/28 00:25
*Lumos Diagnostics Target Price Cut 20% to A$2.00/Share by Bell Potter>LDX.AU
Dow Jones · 10/27 22:07
Lumos Diagnostics Outlines Q1 FY27 Update with Strong Investor Disclaimers
TipRanks · 10/26 23:28
Lumos Diagnostics Boosts FebriDx Sales as U.S. Rollout Accelerates
TipRanks · 10/26 23:27
More
Webull provides a variety of real-time LDXHF stock news. You can receive the latest news about Lumos Diagnostic through multiple platforms. This information may help you make smarter investment decisions.
About LDXHF
Lumos Diagnostics Holdings Limited is an Australia-based company specializes in point-of-care (POC) diagnostic test technology to help healthcare professionals diagnose and manage medical conditions. The Company offers customized assay development and manufacturing services for POC tests and digital reader platforms. It also directly develops, manufactures, and commercializes Lumos-branded POC tests that target infectious and inflammatory diseases. Its Products offering is based on developing and commercializing its own suite of POC diagnostic products which are primarily focused on the diagnosis and management of infectious diseases. These include FebriDx, a POC test for detecting and differentiating viral and bacterial respiratory infections, and ViraDx, a threein-one point-of-care test for influenza A, influenza B and COVID-19. The Company manages the full development program for POC assays.